Know Crohn's.

What it is

Crohn's Disease is a chronic inflammatory disease of the gastrointestinal tract. It can affect any part of the gut from mouth to anus, in patches, and inflames the full thickness of the bowel wall. It's one of two main inflammatory bowel diseases (IBD); the other is ulcerative colitis. Crohn's affects roughly 1 in 200 people in Western countries, with rising incidence globally.

The defining features that distinguish Crohn's from other GI conditions: transmural inflammation (full thickness of the bowel wall, not just the lining), discontinuous disease (patches of inflammation separated by healthy "skip lesions"), and the potential for complications like fistulas, abscesses, and strictures that arise from the depth of the inflammation.

Crohn's is not caused by stress, diet, or anything the patient did. It's a real, biological disease driven by an inappropriate immune response to the gut environment in genetically predisposed people, modulated by microbiome and environmental factors. Decades of patient experience with being told "it's stress" or "try a diet" has made medical mistrust common; modern gastroenterology has moved on.

Disease overview

Crohn's is chronic and relapsing. Most patients move between flares (active inflammation, symptoms) and remission (quiet disease, ideally with healed mucosa). Modern treatment can keep most patients in long remission, but the disease is not cured by medication; stopping treatment in remission usually leads to relapse.

Onset peaks twice in life: late teens to early thirties is the larger peak, with a smaller second peak in the fifties to sixties. Both sexes are affected roughly equally. Smoking meaningfully worsens Crohn's (the one exception to the IBD/smoking story, smoking is mildly protective in ulcerative colitis but actively harmful in Crohn's).

Crohn's vs ulcerative colitis

Both diseases are IBD, but they differ in ways that matter clinically:

• Location. Crohn's: anywhere mouth-to-anus, most often the terminal ileum and right colon. UC: colon only, continuous from the rectum upward.
• Depth. Crohn's: transmural (full thickness). UC: mucosal only (inner lining).
• Pattern. Crohn's: patchy, with skip lesions. UC: continuous.
• Complications. Crohn's commonly causes strictures, fistulas, and abscesses because the inflammation tunnels through the wall. UC mainly causes severe bleeding and toxic megacolon at the worst end.
• Surgery. Colectomy is curative for UC (no colon, no disease). Surgery in Crohn's removes affected segments but the disease can recur elsewhere, often at the surgical anastomosis.
• Smoking. Worsens Crohn's. Mildly protective in UC (do not start smoking).
• Antibodies. ASCA (anti-Saccharomyces cerevisiae) is more common in Crohn's; pANCA is more common in UC. Neither is diagnostic on its own.

Behaviour and location: the Montreal classification

Gastroenterologists describe Crohn's using the Montreal classification, which combines age at diagnosis (A), location (L), and disease behaviour (B). The L and B codes are the practically useful parts:

• L1, ileal. Disease in the terminal ileum (the last part of small bowel). The most common location.
• L2, colonic. Disease confined to the colon. Looks more like UC clinically and on scope.
• L3, ileocolonic. Both ileum and colon involved. Common.
• L4, upper GI. Disease above the terminal ileum (stomach, duodenum, jejunum). Less common, important to recognise.
• B1, inflammatory. Active inflammation without complications. The starting point for most patients.
• B2, stricturing. Narrowing of the bowel that obstructs flow. Often produces post-meal pain and partial obstruction symptoms.
• B3, penetrating. Fistulas (abnormal tunnels), abscesses, sinus tracts. Often requires surgical input as well as medical.
• "p" modifier. Perianal disease (fistulas, abscesses, fissures around the anus) is added as a suffix; significant clinical impact independent of the main B classification.

Disease behaviour evolves. Studies following patients over twenty years show that more than half who start as B1 inflammatory will develop B2 or B3 complications. Early aggressive treatment may slow this progression, which is part of the rationale for early biologic use in moderate-to-severe disease.

Causes and biological mechanisms

Crohn's is not caused by one thing. The current scientific picture combines:

• Genetic predisposition. Over 200 genetic risk loci have been identified. NOD2 variants were the first; they're particularly associated with ileal disease. Family history raises risk meaningfully but most Crohn's patients have no affected first-degree relative.
• Microbiome differences. Crohn's patients have lower gut microbial diversity, reduced anti-inflammatory bacteria (e.g. Faecalibacterium prausnitzii), and increased pro-inflammatory species. Cause-or-consequence is still being worked out.
• Immune dysregulation. An exaggerated mucosal immune response to commensal gut bacteria. Multiple cytokine pathways are involved (TNF-alpha, IL-12/23, IL-23, integrins, JAK/STAT), which is why several biologic classes work.
• Barrier dysfunction. The intestinal epithelial barrier is more permeable in Crohn's, allowing bacterial antigens to provoke immune responses.
• Environmental triggers. Smoking, urban living, antibiotic exposure (especially in childhood), oral contraceptive use, and a Western diet are associated with increased risk. NSAIDs can trigger flares.
• Possible infectious contributions. The role of specific organisms (MAP, AIEC) remains debated and not clinically actionable yet.

Related conditions and overlaps

Crohn's clusters with other immune-mediated inflammatory diseases: axial spondyloarthritis, peripheral arthritis, uveitis, primary sclerosing cholangitis, psoriasis, and other extraintestinal manifestations affect roughly 30% of patients. Chapter six covers each in depth.

Support for family and loved ones

Crohn's is intimate in a way that's hard to discuss. The symptoms are about bathrooms, food, weight, and bodies people don't usually talk about. The loved ones who do best are the ones who get comfortable with the topics: the search for a toilet during a walk, the cancelled dinner, the discreet bag-change in a shared bathroom, the day after a colonoscopy when the patient just needs quiet.

Things that help: being the one who finds the nearest bathroom, choosing accessible restaurants, being calm during embarrassing moments, taking ostomy questions matter-of-factly, learning the signs of a flare before the patient mentions it. Things that hurt: suggesting cures or supplement protocols without being asked, treating the disease as a diet failure, expressing visible discomfort during ostomy care or bathroom topics, asking "are you sure you should be eating that?"

Life around bathrooms

The central practical reality of Crohn's is that the patient's day is organised around the location of the nearest toilet. Long drives become problem-solving exercises. Restaurants are evaluated by their facilities. Films, theatre, queues, public transport, long flights, conference talks: all become risk calculations. Many patients describe years of mapping every bathroom in their neighbourhood, their commute, their workplace.

Apps that locate public toilets are useful tools, not novelties. Aisle seats on planes are non-negotiable. Last-row cinema seats are practical, not antisocial. When you understand a Crohn's patient's seating preferences, you understand most of their week.

Stigma and silence

Most other chronic illnesses don't carry the same social silence. People will discuss their cancer, their MS, their heart attack; they will not, easily, discuss their bowel. The stigma costs Crohn's patients real things: late diagnoses (because the symptoms are too embarrassing to describe to a GP), missed work (because explaining what's actually happening feels impossible), and lost relationships (because the patient never said what was wrong).

Some of the most-shared writing in the Crohn's community is about breaking this silence: the patient who told their workplace what was actually happening and found support instead of judgement; the parent who explained the disease to their child plainly; the partner who learned the right questions. Every patient who speaks honestly about Crohn's makes it easier for the next one.

Ostomy stigma

An ostomy is a surgical opening on the abdomen where bowel exits into a pouch attached to the skin. For many Crohn's patients (and most UC patients who choose colectomy), it is the single best quality-of-life decision they make. The reputation is much worse than the reality.

Pre-surgery, most patients fear loss of intimacy, loss of body confidence, social isolation, and a smaller life. Post-surgery, the most common reported reaction is: "I should have done this years ago." Studies consistently show ostomy patients' quality-of-life ratings rise meaningfully after the procedure once they have settled. Modern stomas are flat, well-designed, mostly invisible under clothing. Patients can swim, run, lift, work, parent, be intimate, and travel.

What the ostomy community asks of everyone else: do not flinch. Do not treat it as visible damage. Treat it as the practical solution it usually is.

The Crohn's tax

The financial cost of Crohn's is significant and rarely discussed. The line items add up:

• Biologic medications. Even with insurance, copays and deductibles for biologics can run thousands per year. Without insurance, list prices are often $40,000+/year.
• Frequent specialist visits. Gastroenterology, rheumatology, dermatology, ophthalmology, surgery, nutrition. Each appointment costs time, money, or both.
• Imaging and procedures. Colonoscopies, MR enterograms, CT scans add up over a lifetime of monitoring.
• Time off work. For flares, infusions, procedures, recovery. Unpaid leave or sick-day depletion is common.
• Food. Specialised diets, formula nutrition during EEN, restricted diets that limit cheaper options.
• Ostomy supplies. Largely covered by insurance in some countries, partly or not at all in others. Hidden recurring cost.
• Travel-related costs. Aisle seats, extra hotel nights for proximity to specialist centres, taxis on flare days.

Patients who manage the financial burden well usually do three things early: get on the disability and insurance paperwork before they need to, learn the patient-assistance programmes for their biologic, and find an IBD-experienced social worker if available.

Impact on identity

Crohn's frequently strikes in the late teens and twenties, the years when identity is being built. Patients describe losing the version of themselves who could go out without planning, who could eat freely, who could trust their body. Rebuilding an identity around a body that is unreliable about food, energy, and time is some of the harder work of living with this disease.

The patients who do this well almost universally describe the same arc: years of fighting the disease, hitting a wall, accepting the disease as a constraint to design around, then finding meaning and capability inside the constraint. This is integration, not surrender.

Mental health

Anxiety and depression are well above population baseline in Crohn's. The drivers are concrete: years of bathroom anxiety, social withdrawal during flares, chronic pain, financial stress, medication side effects (especially steroids), and the cognitive load of a disease that requires constant management. These are largely consequences of living with the illness, not the cause of it.

Treatment is worthwhile. Many of the standard antidepressants work well in Crohn's; trauma-focused therapy can help patients who have been through severe flares, hospitalisations, or surgical complications. The gut-brain axis is real but not magical; treating depression makes life better, but it does not make Crohn's quiet.

Crohn's symptoms vary by location, behaviour, and severity. The list below is comprehensive, not a checklist. No patient has every symptom, and the same patient's pattern shifts over years.

GI symptoms

Diarrhoea

The most common symptom. Crohn's diarrhoea is often less bloody than UC (because the inflammation is patchy and may not involve the rectum), but it's still common in colonic disease. Frequency varies from a few extra trips per day in mild disease to over twenty per day in severe flares. Urgency is its own dimension; many patients describe needing the bathroom within seconds of feeling the signal.

Abdominal pain

Most commonly right lower quadrant (terminal ileum disease), often worse after eating ("postprandial pain"). Crampy pain that comes in waves is characteristic. Severe or constant pain, particularly with vomiting or bloating, can indicate a stricture causing partial obstruction; this is a reason to call your team.

Rectal bleeding

Common in colonic Crohn's, rare in pure ileal disease. New bleeding warrants a calprotectin and a conversation with your team; persistent bleeding warrants a scope.

Mouth and upper-GI symptoms

Mouth ulcers (aphthous) are common during active disease. Upper GI Crohn's (oesophageal, gastric, duodenal) is less common but can present with reflux, nausea, vomiting, or upper abdominal pain that gets misdiagnosed as standard reflux disease.

Vomiting and obstruction

Vomiting, abdominal distension, and inability to pass gas suggests a stricture causing obstruction. This is a clinical emergency requiring imaging and surgical input.

Perianal disease

Perianal Crohn's affects roughly a fifth of patients and is significant enough to be a separate clinical problem. Manifestations include:

• Skin tags. Often the earliest sign; can predate gut diagnosis.
• Fissures. Painful tears in the anal canal.
• Abscesses. Pockets of pus that often present as severe perianal pain and require surgical drainage.
• Fistulas. Abnormal tunnels between the bowel and skin (or other organs). Can be simple or complex; complex fistulas are some of the harder problems in IBD care.
• Strictures. Narrowing of the anal canal causing difficult or painful defaecation.

Perianal disease changes the treatment urgency. Combined medical (anti-TNF is the best-evidenced biologic for perianal disease) plus surgical (seton placement, abscess drainage) management led by both gastroenterology and colorectal surgery is standard.

Extraintestinal manifestations

Roughly 30% of Crohn's patients develop disease outside the gut. The pattern matters because some EIMs track with gut activity (treating the gut treats them) and some are independent (need their own treatment).

Joint disease

Axial spondyloarthritis (axSpA). Inflammatory lower-back and sacroiliac joint pain, worse at rest, better with movement, often morning-predominant. Independent of gut activity; needs rheumatology input and often its own treatment (anti-TNF is often the best joint+gut option). Can predate gut diagnosis by years.

Peripheral arthritis. Two patterns: pauciarticular (few joints, large joints, often follows gut activity) and polyarticular (many joints, small joints, more chronic, less linked to gut activity).

Eye disease

Episcleritis (redness, mild discomfort, no vision threat) usually tracks with gut activity. Uveitis (pain, light sensitivity, blurred vision) is more serious and requires urgent ophthalmology; can cause permanent vision damage if untreated. Anti-TNF biologics often treat both eye and gut disease.

Skin

Erythema nodosum. Tender, red, raised nodules, typically on the shins. Usually tracks with gut activity.

Pyoderma gangrenosum. Painful, ulcerating skin lesions, often near surgical sites or on legs. Independent of gut activity. Difficult to treat; often needs anti-TNF or other biologics.

Sweet syndrome. Less common; tender red plaques, fever, neutrophilia.

Liver and biliary

Primary sclerosing cholangitis (PSC). Progressive inflammation and scarring of the bile ducts. Rare but serious. Increases risk of cholangiocarcinoma and colorectal cancer. LFTs (especially ALP) should be checked at least annually in all Crohn's patients.

Other

Anaemia (iron deficiency from chronic blood loss and inflammation; B12 deficiency from terminal ileal disease or resection), osteoporosis (chronic inflammation plus steroid history), kidney stones (oxalate stones after bowel resection or with fat malabsorption), gallstones (especially after terminal ileal resection).

Nutritional deficiencies

Nutritional deficiencies are routine in Crohn's and worth checking at least annually:

• Iron. From chronic blood loss, inflammation reducing iron absorption, and gut dysfunction. Ferritin under 75 is functionally deficient; ferritin under 30 is absolute deficiency. IV iron is often more effective than oral.
• Vitamin B12. The terminal ileum absorbs B12. Terminal ileal disease or resection causes deficiency. Often requires lifelong injections.
• Vitamin D. Low in most Crohn's patients. Replete to mid-normal range; influences both bone health and possibly disease activity.
• Folate. Particularly important on methotrexate or with small-bowel disease.
• Zinc. Wound healing, immune function. Worth checking with chronic diarrhoea.
• Calcium. Bone health, especially after steroid courses or with malabsorption.
• Magnesium. Lost with chronic diarrhoea.
• Fat-soluble vitamins (A, D, E, K). Particularly with fat malabsorption (steatorrhoea, after ileal resection).

Fatigue

Disproportionate fatigue is one of the most common and most under-treated Crohn's symptoms. Drivers include active inflammation itself (cytokines drive fatigue), anaemia (iron, B12), sleep disruption from bathroom trips, chronic pain, depression, and the cognitive load of managing the disease. Treating the underlying drivers usually helps; "you should rest more" rarely does.

Weight loss and malnutrition

Weight loss in Crohn's has multiple drivers: reduced intake (food aversion, fear of eating, restriction during flares), malabsorption (especially with extensive small-bowel disease or after resection), and the catabolic state of chronic inflammation. Significant unexplained weight loss is a red flag that warrants calprotectin and review. Weight regain is often the most visible sign that mucosal healing has been achieved.

Diagnostic workup

Diagnosis is a combination of clinical history, endoscopic findings with biopsy, cross-sectional imaging, and supportive bloods. No single test is definitive.

• Ileocolonoscopy with biopsy. The cornerstone. Direct visualisation of the terminal ileum and colon plus biopsies for histology (looking for granulomas, transmural inflammation, skip lesions).
• Cross-sectional imaging. MR enterography is preferred (no radiation, excellent small-bowel visualisation, identifies strictures and fistulas). CT enterography is faster but uses radiation. Bowel ultrasound is rising in IBD centres with expertise; cheap and repeatable.
• Capsule endoscopy. Useful for suspected small-bowel disease beyond reach of standard scope. Contraindicated if a stricture is suspected (the capsule can get stuck).
• Bloods. FBC (anaemia, white cell count), CRP (inflammation), ESR, ferritin, B12, folate, vitamin D, LFTs (PSC screening), U&E, magnesium, albumin (a low albumin in active disease is meaningful).
• Faecal calprotectin. The single most useful non-invasive marker. Sensitive for active intestinal inflammation. Cheap. Used both for diagnosis and ongoing monitoring.
• Stool studies. Rule out infectious causes of diarrhoea (Salmonella, Shigella, Campylobacter, C. diff, parasites). Important at initial workup and during flares (C. diff can mimic or coexist with a flare).
• Antibodies. ASCA (more Crohn's) and pANCA (more UC) can help distinguish IBD subtypes but are not diagnostic alone.

Calprotectin and ongoing monitoring

Faecal calprotectin deserves its own section because it's central to modern IBD management. The protein is released by neutrophils, and elevated levels indicate intestinal inflammation. Compared to other tools, it is:

• Non-invasive. A stool sample at home, posted to the lab.
• Cheap. Tens of dollars vs. hundreds for a scope.
• Sensitive. Catches subclinical inflammation that the patient cannot feel.
• Quantitative. Trends matter, not just single results.

Knowing your individual normal-when-well baseline matters more than chasing a population threshold. A patient whose well baseline is 50 µg/g should worry if it rises to 200; another whose well baseline is 250 may not. Test every few months and during any symptom change.

Differential diagnosis

Conditions that can mimic Crohn's or coexist:

• Ulcerative colitis (often the main alternative; in 5-15% of IBD cases the distinction remains unclear: "IBD-unclassified").
• Intestinal infections (Yersinia, Campylobacter, TB enteritis in endemic regions).
• Coeliac disease.
• Microscopic colitis (causes chronic watery diarrhoea with a normal-looking colon on scope; needs biopsies).
• Irritable bowel syndrome (can coexist; calprotectin is normal in IBS).
• Endometriosis (can mimic ileal Crohn's with cyclical pain).
• Diverticular disease.
• Behçet's disease.
• NSAID enteropathy.
• Lymphoma (rare but worth ruling out in atypical cases).

Treatment framework

Modern Crohn's treatment is treat-to-target: the goal is not just symptom relief but objective mucosal healing on scope and normal calprotectin. Patients who achieve this have meaningfully better long-term outcomes (fewer surgeries, fewer hospitalisations, slower progression of disease behaviour).

The treatment ladder is roughly:

1. Induce remission (steroids, EEN, sometimes biologics).
2. Maintain remission (immunomodulators, biologics, surgery for localised disease).
3. Monitor with calprotectin and periodic scope.
4. Escalate or switch when targets aren't met.

Patient selection between agents is driven by disease severity, location, behaviour, comorbidities, and patient preference. Modern IBD is highly individualised; the same patient might be on infliximab, vedolizumab, and risankizumab in different decades.

Steroids and budesonide

Steroids (prednisolone) work fast and reliably for inducing remission in a flare. They do not maintain remission and have significant side effects with prolonged use: bone loss, weight gain, mood disturbance, blood sugar, infection risk, cataracts, adrenal suppression.

Budesonide (Entocort, Cortiment) is a steroid with high first-pass liver metabolism, so it has fewer systemic side effects. Useful for mild-to-moderate ileal or right-colonic Crohn's. Same principle: induction, not maintenance.

If you find yourself on repeated steroid courses or unable to taper off, that is a clear signal the underlying maintenance treatment needs to escalate. Steroid dependence is itself a disease-severity indicator.

Immunomodulators

• Azathioprine / 6-mercaptopurine. Older immunomodulator. Slow onset (3-6 months). Used as monotherapy in some milder cases, or in combination with anti-TNF to reduce antibody formation. Check TPMT activity before starting; monitor FBC and LFTs.
• Methotrexate. Used when thiopurines are not tolerated. Weekly oral or subcutaneous. Always with folate. Strictly contraindicated in pregnancy (and pre-pregnancy in both partners).

The biologic landscape

Biologics revolutionised Crohn's care over the last two decades. The major classes:

• Anti-TNF (infliximab, adalimumab, certolizumab). The first biologics. Effective for moderate-to-severe Crohn's, including perianal disease and extraintestinal manifestations. Often given with an immunomodulator to reduce antibody formation. Watch for opportunistic infections; screen for latent TB and hepatitis B before starting.
• Anti-IL12/23 (ustekinumab). Blocks IL-12 and IL-23 cytokines. Effective in Crohn's including in anti-TNF-experienced patients. Generally better-tolerated than anti-TNF.
• Anti-IL23 (risankizumab, mirikizumab). Newer, more selective blockade of just IL-23. Strong efficacy data; emerging as first-line option in some centres.
• Anti-integrin (vedolizumab). Gut-selective; blocks lymphocyte trafficking to the gut. Lower systemic immunosuppression, which makes it attractive in older patients or those with infection concerns. Slower onset.
• Natalizumab. Broader integrin blockade. Risk of PML (a rare brain infection) has limited use; reserved for selected cases.

Drug-level monitoring (trough levels and anti-drug antibodies) is increasingly standard for anti-TNF, allowing dose optimisation when patients seem to lose response. About a third of patients lose response to a first biologic in the first year; switching to a different mechanism class often works better than switching within the same class.

JAK inhibitors

Upadacitinib (Rinvoq) is the JAK inhibitor approved for Crohn's. Oral (not infusion or injection), rapid onset. Effective in moderate-to-severe Crohn's including in patients who have failed biologics. Boxed warnings around cardiovascular events, malignancy, and serious infection mean it's typically used after biologic failure rather than first-line, particularly in older patients or those with cardiovascular risk.

Surgery

Surgery is part of Crohn's treatment, not a sign of failure. Roughly half of Crohn's patients have at least one surgery in their lifetime, more in stricturing or penetrating disease. Common procedures:

• Ileocaecal resection. Removing the terminal ileum and caecum. The most common Crohn's surgery. For localised B2 stricturing disease, it's often the best treatment available; many patients have years of remission afterward.
• Strictureplasty. Widening a stricture without removing bowel. Used when strictures are multiple or in patients with limited remaining small bowel.
• Segmental colectomy. Removing a section of colon.
• Subtotal colectomy with end ileostomy. For severe colonic Crohn's; results in an ostomy.
• Drainage of abscess, seton placement. For perianal disease.
• Fistula repair. Often complex, multi-stage.

Post-operative recurrence is real: about half of patients will have endoscopic recurrence at the anastomosis within a year, though clinical recurrence is slower. Post-operative biologic or immunomodulator therapy reduces recurrence and is increasingly standard in high-risk patients (penetrating disease, perianal disease, smokers, prior resection).

What helps versus what harms

Experimental and emerging treatments

• Anti-TL1A (tulisokibart, others). One of the most-watched new classes; targets a cytokine implicated in fibrosis as well as inflammation. Phase 3 trials are running. Promise: a drug that addresses stricturing disease, not just inflammation.
• Microbiome therapies. Faecal microbiota transplantation (FMT) has shown efficacy in C. diff and some signal in UC; Crohn's evidence is weaker. Defined microbial consortia are in trials.
• Stem cell therapy. Mesenchymal stem cells (Alofisel) are approved in some regions for refractory perianal fistulas in Crohn's. Hematopoietic stem cell transplant remains experimental for severe refractory disease, with significant risk.
• JAK1-selective and TYK2 inhibitors. Newer JAK-family drugs may offer the efficacy with a cleaner safety profile.
• Anti-MAdCAM (etrasimod, others) and S1P modulators. Gut-selective immune-trafficking blockers; ulcerative-colitis evidence is stronger, Crohn's trials ongoing.
• Exclusive enteral nutrition (EEN). A formula-only diet for 6-8 weeks. Strong evidence for inducing remission, especially in paediatric Crohn's. Underused in adults.
• Dietary therapies under study. CDED, specific carbohydrate diet, low-FODMAP, anti-inflammatory diet for IBD (Konijeti). None replace medical therapy, but some are useful adjuncts.

Tools, apps, and the kit patients actually use

Tracking and monitoring

• Rox. The companion app this reference is built alongside. Tracks symptoms, biologic injection dates and infusion days, calprotectin trends, flares, and the patterns across food, sleep, and stress that change your week. Built-in flare-pattern detection; turns months of data into the picture your gastroenterologist actually wants. App Store.
• Calprotectin home-collection kits. Many countries now offer postal home-collection. Cheap, useful between scopes.
• Symptom diaries. Even a simple log of bowel frequency, urgency, pain, and weight is useful at appointments. A two-week log before a scope is worth more than memory.

Bathroom and access tools

• Toilet finder apps (Toilet Finder, Flush, We Can't Wait, country-specific versions). Map every public toilet near you; some include accessibility info.
• Toilet access cards. Crohn's & Colitis UK's "Can't Wait" card, Crohn's & Colitis Foundation's "I Can't Wait" cards in the US. A small card to show staff in restaurants, shops, and public buildings, explaining you need urgent toilet access for medical reasons.
• Radar key (UK). Universal key for accessible disabled toilets. Worth carrying.
• Travel certificate / medication letter. For flying with biologics that need cold storage, sharps, and ostomy supplies.

Ostomy and bag kit

• Stoma nurse contact details. The most underused resource. Stoma nurses solve practical problems faster than gastroenterologists. Get the number on day one.
• Spare bag kit in your bag, your car, and your desk. Wet wipes, adhesive remover, pouch, flange, disposal bags.
• Higher-capacity night drainage bag if night-time output is an issue.
• Convex appliances for retracted stomas. Don't tolerate leaks; switch product if the system isn't working.

Food kit

• Low-residue go-to foods stocked at home for flare days (white rice, banana, applesauce, toast, plain chicken, broth).
• Oral nutritional supplements (Ensure, Fortisip, Modulen) for weight maintenance during flares.
• Pre-packed safe-food snacks for travel, work, and unpredictable meals out.

Finding the right clinician

• Crohn's & Colitis Foundation (US) physician finder.
• Crohn's & Colitis UK resources and local network.
• ECCO (European Crohn's and Colitis Organisation) for European clinicians.
• Specialist IBD centres are usually worth the travel for complex cases (failed biologics, complex perianal disease, planning surgery).

Prognosis

Prognosis in Crohn's has improved dramatically over the past two decades, mostly because of biologics, mucosal-healing as a treatment target, and better surgical timing. The honest summary:

• Most patients reach long stretches of remission with modern treatment.
• Disease behaviour evolves: most patients who start as B1 inflammatory will develop B2 stricturing or B3 penetrating complications over decades, though early aggressive treatment may slow this.
• Roughly half of patients will have at least one surgery in their lifetime. This is not a failure; for many, surgery is the best treatment available.
• Life expectancy is close to normal for most patients with modern care. Excess mortality is concentrated in severe phenotypes (extensive small-bowel disease, frequent surgeries, refractory perianal disease) and is influenced by smoking, steroid burden, and untreated comorbidities.
• Crohn's modestly increases risk of colorectal cancer in long-standing colonic disease (managed by surveillance) and small-bowel cancer in long-standing small-bowel disease.

Diet, without dogma

The honest answer to "what should I eat" is: it depends on your disease phenotype, behaviour, and current activity. There is no single Crohn's diet.

What has the strongest evidence:

• Exclusive enteral nutrition (EEN). A formula-only diet for 6-8 weeks induces remission, with strong evidence especially in paediatric Crohn's. Hard to sustain but works well as an alternative to steroids when a flare needs treating.
• Crohn's Disease Exclusion Diet (CDED). Structured diet developed in Israel, often combined with partial enteral nutrition. Emerging evidence for inducing and maintaining remission.
• Mediterranean diet. Anti-inflammatory in general; reasonable default in remission.

What to be careful with:

• Blanket fibre restriction. Avoid only if you have a known stricture or are in a flare. In remission, most patients tolerate normal fibre, and prolonged fibre restriction worsens microbiome diversity.
• Restrictive elimination diets without supervision. Paleo, AIP, carnivore, juicing, and similar can cause weight loss and nutritional deficiencies that worsen Crohn's outcomes.
• Probiotics off the shelf. Weak Crohn's evidence; save the money.

During a flare, lower-residue foods (white rice, banana, applesauce, toast, plain chicken, broth) are easier on irritated bowel. In remission, most patients return to normal diets with individual tolerance adjustments.

Work and insurance

Crohn's intersects with work in ways that can be navigated with planning:

• Disclosure. You're under no obligation to disclose, but disclosure to a trusted manager often unlocks accommodations (flexible hours, bathroom access, remote-work days during flares, accommodation for biologic infusions).
• Insurance and biologics. Biologic copays can be substantial. Manufacturer patient-assistance programmes (Remicade Care, AbbVie's Adalimumab assist, Stelara Connect, etc.) often reduce out-of-pocket costs significantly. Don't pay the sticker price without checking.
• Disability paperwork. Start during a flare. Document everything (bathroom frequency, missed work, hospital admissions). Crohn's disability claims often go through; many patients underestimate eligibility.
• FMLA / equivalents. Job-protected leave for biologic infusions, hospitalisations, and recovery. Worth setting up proactively.
• Health insurance and job changes. Continuity of biologic coverage is a real consideration; the cost of a coverage gap or switching to a non-formulary biologic can be high. Plan job moves around biologic timing where possible.

Fertility and pregnancy

Crohn's and fertility:

• Female fertility is normal in patients with quiescent disease. Active disease, prior surgery (especially involving the pelvis, e.g. proctocolectomy with IPAA), and pelvic adhesions can reduce fertility. Pre-conception counselling is worth pursuing.
• Male fertility. Most Crohn's medications don't affect male fertility. Sulfasalazine is the exception; it reversibly reduces sperm count.

Crohn's and pregnancy:

• Conception in remission. The strongest predictor of a good pregnancy outcome. Active disease at conception correlates with worse outcomes for both pregnancy and the disease.
• Continuing biologics in pregnancy. Most biologics (anti-TNF, ustekinumab, vedolizumab) are pregnancy-compatible. Stopping them carries a flare risk that is worse for the pregnancy than the medication. The most common error is patients stopping biologics in early pregnancy and flaring badly.
• Contraindicated. Methotrexate (strict, both partners pre-conception too). JAK inhibitors are not recommended.
• Delivery. Mode of delivery is usually determined by obstetric factors, not Crohn's. Perianal disease may favour Caesarean.
• Breastfeeding. Most biologics are compatible (large molecules; minimal transfer into breast milk).

The right team: an IBD-experienced gastroenterologist working with an obstetrician familiar with IBD pregnancies, started before conception where possible.

Ostomy life

For Crohn's patients who end up with an ostomy (often after subtotal colectomy or for severe perianal disease), the lived reality is consistently better than the pre-surgery picture. Practical notes:

• Day one to month three. Real adjustment period. Stoma nurse is essential. Trial different appliance brands; what works for one patient won't for another.
• Activities. Most ostomy patients swim (with a flat or convex appliance), exercise, lift weights (with abdominal support), travel internationally, work physical jobs, and parent.
• Intimacy. Sex with an ostomy is normal and possible. The first few times require practical conversations (appliance type, position, timing) but most couples adapt within months. Patient communities are matter-of-fact about this; the medical world is often more squeamish than the patients.
• Clothing. Modern flat appliances are largely invisible under normal clothes. Specialised ostomy underwear exists; many patients don't need it.
• Travel. Carry extra supplies (more than you think). Bring an emergency change kit. Letter from your team explaining the stoma for airport security. Aisle seat. Most patients travel internationally without issue after the first trip.
• Diet. Mostly normal. A few foods cause more output or block more easily (raw vegetables, mushrooms, nuts, popcorn); experimentation tells you what your stoma tolerates.

Travel

Travel with Crohn's is possible and worth doing. Planning beats spontaneity:

• Carry a written treatment summary, medication list, and emergency contact for your gastroenterologist.
• Carry biologic injections in a cool pack with a letter from your clinic for airport security and customs.
• Carry enough supplies (biologics, ostomy supplies, low-residue snacks) for the trip plus a delay.
• Research IBD-aware clinicians at your destination in case of flares. ECCO and Crohn's & Colitis Foundation have international IBD-centre maps.
• Travel insurance that covers pre-existing IBD; declare it carefully.
• Aisle seat. Always.

Adapting life around the illness

The patients who live well with Crohn's almost universally describe the same arc: years of fighting the disease, hitting a wall, accepting it as a constraint to design around, then finding meaning and capability inside the constraint. Practical engineering that helps:

• Plan around bathroom access without making it the centre of every decision.
• Build a flare kit that lives in your bag, your car, and your desk.
• Have go-to safe foods stocked at home.
• Pre-empt the conversation with employers, partners, and close friends so you're not explaining at 6 a.m. on a bad day.
• Get a stoma nurse number in your phone whether or not you have a stoma.
• Treat surveillance scopes as routine maintenance, not catastrophes to dread.

Crohn's doesn't only live in the gut. Roughly 30% of patients develop extraintestinal manifestations (EIMs) over their lifetime. Some EIMs track with gut activity (treating the gut treats them); others are independent and need their own treatment. Recognising the overlaps matters because some EIMs predate the gut diagnosis by years.

Axial spondyloarthritis (axSpA)

Inflammatory arthritis of the spine and sacroiliac joints. Classic features:

• Lower back and buttock pain, often alternating sides.
• Worse at rest, better with movement (inverse of mechanical back pain).
• Morning stiffness lasting over an hour.
• Onset typically under age 45.
• Improves with NSAIDs (which carry their own Crohn's complications).

axSpA is independent of gut activity. It needs rheumatology input. Anti-TNF biologics often treat both joints and gut and are the preferred choice when both are active. Untreated axSpA can cause permanent spinal fusion over decades; early diagnosis matters.

Peripheral arthritis

Two patterns:

• Type 1 (pauciarticular). Few joints, larger joints (knees, ankles, wrists), asymmetric. Often tracks with gut activity, so treating the gut treats the joints.
• Type 2 (polyarticular). Many joints, smaller joints (hands), symmetric. More chronic, less linked to gut activity. Often needs its own treatment.

Uveitis

Eye inflammation, more serious than the milder episcleritis. Symptoms: pain, redness, light sensitivity, blurred vision, sometimes floaters. Uveitis is an ophthalmological emergency that can cause permanent vision damage if not treated quickly. Any of these symptoms in a Crohn's patient warrants same-day ophthalmology.

Episcleritis is the milder cousin: redness, mild discomfort, no vision threat. Usually tracks with gut activity and resolves with disease control.

Primary sclerosing cholangitis (PSC)

Progressive inflammation and scarring of the bile ducts (the tubes that carry bile from liver to intestine). Rare in Crohn's, more common with colonic Crohn's and UC. Asymptomatic in early stages; later causes fatigue, itching, jaundice. Diagnosed by elevated alkaline phosphatase (ALP) on LFTs and confirmed by MRCP or ERCP imaging.

PSC matters because:

• It is the leading cause of cholangiocarcinoma in IBD patients.
• It substantially increases colorectal cancer risk in patients with concurrent IBD; surveillance intervals tighten.
• It can progress to liver failure requiring transplant.
• There is no medical treatment that reliably halts progression.

Annual LFTs (especially ALP) should be checked in all Crohn's patients. Persistent ALP elevation warrants MRCP.

Skin manifestations

Erythema nodosum

Tender, red, raised nodules, typically on the shins. Painful but not vision- or limb-threatening. Usually tracks with gut activity and resolves with treatment of the underlying flare.

Pyoderma gangrenosum

Painful ulcerating skin lesions that start as papules and rapidly expand. Often near surgical sites or on the legs. Independent of gut activity. Difficult to treat; often requires anti-TNF or other biologics. Frequently misdiagnosed initially as infection, leading to harmful debridement (pathergy makes PG worse with surgical interference).

Other

Sweet syndrome (tender red plaques with fever), aphthous stomatitis (mouth ulcers, common), perianal skin changes, psoriasis (paradoxically can be triggered by anti-TNF in some patients).

Kidney and gallstones

Kidney stones

Crohn's patients, especially after ileal resection or with extensive small-bowel disease, are at risk for oxalate kidney stones. The mechanism: fat malabsorption binds calcium in the gut, leaving oxalate free to be absorbed and excreted in urine. Low-oxalate diet, adequate calcium intake, and hydration help.

Gallstones

After terminal ileal resection or extensive ileal disease, bile salt reabsorption is impaired, predisposing to gallstones. Symptomatic stones may need cholecystectomy.

Bone health

Crohn's patients are at significantly elevated risk of osteopenia and osteoporosis. Drivers: chronic inflammation, steroid courses, vitamin D and calcium deficiency, low BMI, smoking. Even young Crohn's patients can have meaningful bone loss.

DEXA scan is worth requesting if you've had multiple steroid courses, have a low BMI, are postmenopausal, or have a strong family history of osteoporosis. Vitamin D and calcium repletion, weight-bearing exercise, smoking cessation, and bisphosphonates where appropriate all help.

Cancer surveillance

Crohn's modestly increases risk of several cancers:

• Colorectal cancer. Elevated in long-standing colonic Crohn's, especially with extensive colonic involvement and concurrent PSC. Surveillance colonoscopy starts 8-10 years after diagnosis for colonic Crohn's; intervals depend on findings.
• Small-bowel cancer. Rare overall, but elevated in long-standing small-bowel Crohn's. Difficult to screen for routinely; imaging during workups helps.
• Lymphoma. Small increase in patients on long-term thiopurines (azathioprine, 6-MP), particularly young men. Hepatosplenic T-cell lymphoma is the rare worst-case association.
• Skin cancer. Anti-TNF biologics increase non-melanoma skin cancer risk modestly. Annual skin checks, especially with sun exposure history, are sensible.
• Cholangiocarcinoma. Markedly elevated in patients with PSC. Worth knowing about; not common.

None of these change the overall picture: untreated active inflammation does more harm than the medications. The medications carry small, manageable cancer risks; the disease carries larger, less manageable ones.

The current scientific picture

Crohn's is understood as a chronic immune-mediated disease driven by an inappropriate mucosal immune response to gut microbial antigens in genetically predisposed people. Key mechanistic insights of the past decade:

• Multiple immune pathways. TNF-alpha was the first, but IL-12, IL-23, integrins (α4β7), JAK/STAT, and now TL1A all matter. Different patients respond to different mechanisms; combination biologic therapy is being explored.
• Microbiome involvement. Crohn's patients have lower microbial diversity, reduced anti-inflammatory species (Faecalibacterium prausnitzii), and increased pro-inflammatory species (adherent-invasive E. coli). Cause-vs-consequence is still being worked out.
• Mucosal barrier dysfunction. Increased intestinal permeability appears both genetically driven and inflammation-driven.
• Fibrosis as a separate process. Stricturing disease involves not just inflammation but fibrotic remodelling of the bowel wall. Anti-inflammatory drugs alone don't reverse fibrosis. Anti-TL1A may.
• Mucosal healing as a meaningful endpoint. Patients who achieve endoscopic and histological healing have fewer surgeries, fewer hospitalisations, slower behaviour progression, and lower cancer risk.

Historical timeline

Active research directions

• Anti-TL1A drugs. Tulisokibart (Prometheus, now Merck) and similar agents target TL1A, a cytokine involved in both inflammation and fibrosis. Phase 3 trials are running; promise of an anti-fibrotic effect in addition to anti-inflammatory.
• Anti-IL23p19 expansion. Risankizumab and mirikizumab data in real-world settings; comparative trials against existing biologics.
• Combination biologic therapy. The VEGA trial (golimumab + guselkumab) and others are exploring whether combining mechanism classes can deliver higher remission rates than monotherapy.
• Microbiome therapeutics. Defined microbial consortia (e.g. SER-287) and FMT trials in IBD. UC evidence is stronger than Crohn's; the work continues.
• Stem cell therapy. Mesenchymal stem cell therapy (Alofisel/darvadstrocel) for refractory perianal fistulas is approved in some regions. Autologous hematopoietic stem cell transplant for severe refractory disease remains experimental.
• Drug-level monitoring optimisation. Proactive monitoring of anti-TNF trough levels and antibodies as standard of care is reshaping how patients are managed.
• Patient-derived organoids. Using a patient's own intestinal cells to screen which biologic is most likely to work for them. Years from clinic but actively researched.
• AI-assisted endoscopy. Computer-assisted reading of colonoscopy footage to detect subtle disease activity and dysplasia. Already entering some centres.

Key sources worth knowing

• Crohn's & Colitis Foundation (US). The dominant US patient advocacy and research-funding organisation. Patient resources, clinical guidelines, research grants, IBD Help Center.
• Crohn's & Colitis UK. UK-based with strong patient resources including the "Can't Wait" toilet access card.
• ECCO (European Crohn's and Colitis Organisation). The European clinical and research society. Publishes some of the most-used clinical guidelines.
• AGA, BSG, AGA Crohn's Guidelines. The American Gastroenterological Association and British Society of Gastroenterology publish regularly updated clinical guidance.
• UpToDate IBD chapters. Behind a paywall but the most-used clinician reference; many institutions have access.
• IBD Patients Society and Reddit r/CrohnsDisease, r/ostomy. Patient-to-patient knowledge, especially on practical things (biologic injection sites, ostomy products, travel hacks) that don't make it into clinician guidelines.

Content creators worth knowing

The Crohn's creator landscape, judged by what actually surfaces in r/CrohnsDisease and r/UlcerativeColitis threads, is dominated by diet protocols, organisations, and educators rather than YouTube-personality creators. That's a signal in itself: when biomarkers are concrete (calprotectin, scope), the most-shared content tends to be about what works, not about who's saying it.

Organisations and education

Diet protocols (used widely; evidence varies)

Virtual care and tools

The contested zone, recovery protocols and elimination-diet content

A smaller industry markets "natural Crohn's recovery" through restrictive diets and supplement protocols. Less harmful than the brain-retraining ecosystem in ME/CFS (because IBD biomarkers make outcome claims checkable), but worth approaching skeptically.

Resources and community

• r/CrohnsDisease and r/ostomy on Reddit. Practical, lived-experience-rich, surprisingly civil for chronic-illness subs.
• Crohn's & Colitis Foundation local chapters (US). In-person and online support groups, education events, awareness walks.
• IBD Help Center (Foundation, US). Direct support for navigating diagnosis, treatment access, insurance.
• Stoma nurse at your hospital or clinic. Often the most useful single contact for practical ostomy questions.
• Country-specific IBD charities. Most countries have an equivalent of the US/UK organisations; worth finding the local one.

Where to start if you've just been diagnosed

1. Find an IBD-experienced gastroenterologist. Specialised IBD centres are worth the travel.
2. Get a baseline calprotectin, full nutritional bloods, and a treatment plan that aims for mucosal healing.
3. Discuss biologic strategy early, even if you don't start on one immediately. Know what your first biologic would be, why, and what the backup is.
4. Quit smoking. The single largest controllable variable that worsens Crohn's.
5. Build a flare plan, a bathroom-finder strategy, and a kit. Don't wait for the first bad week.
6. Get the disability and insurance paperwork started early.
7. Find one reliable patient-community space and one trusted clinical information source. Beware of cure protocols.

About this reference

This is a living document. It will be updated as new research emerges, as community-sourced Reddit research lands, and as patients tell us what is missing. The medical claims here are drawn from major IBD guidelines (ECCO, AGA, BSG), the listed organisations, and the published Crohn's literature. None of this is personal medical advice. For your situation specifically, talk with an IBD-experienced gastroenterologist.